Les Laboratoires Servier SAS - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
95
About the Report
About the Report
Summary
Les Laboratoires Servier SAS (Servier) researches, develops, manufactures and markets drugs for treating various diseases. The company's portfolio of marketed products treat central nervous system (CNS) disorders, cardiovascular diseases, cancer, ENT disorders, respiratory diseases, women's and male health issues, gastrointestinal diseases, hematological disorders, hormonal disorders and others. It invests substantial amount of revenue in R&D. Servier operates research centers in France and Hungary; and International Centers for Therapeutic Research (ICTRs) worldwide. The company also provides generic drugs and contract development and manufacturing services across its global network. Servier sells its products in Europe, North America, South America, Middle East, Africa and Asia. Servier headquartered in Suresnes, France.
Les Laboratoires Servier SAS-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Les Laboratoires Servier SAS, Medical Devices Deals, 2012 to YTD 2018 11
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deal Details 16
Asset Purchase 16
Les Laboratoires Servier Acquires Oncology Business from Shire for USD2.4 Billion 16
Egis Pharma Acquires Sorbifer Rights from AstraZeneca 18
Venture Financing 19
Ilkos Therapeutics Raises USD14 Million in Seed Financing 19
Partnerships 20
Laboratorios Farmaceuticos Rovi Enters into Agreement with Biogaran 20
Les Laboratoires Servier and ScandiCure Enter into Agreement 21
ImmunoQure Enters into Agreement with Servier 22
Les Laboratoires Enters into Agreement with Treventis 23
Les Laboratoires Servier Enters into Agreement with Harvard University 24
Philochem Enters into Research Agreement with Les Laboratoires Servier 25
Servier and Transgene Enters into Research Agreement 26
Vernalis and Servier Enter into Discovery Agreement 27
Les Laboratoires Servier and Masthercell Enter into Agreement 28
Les Laboratoires Servier Enters into Research Agreement with Center for Applied Medical Research 29
Daiichi Sankyo Enters Into Marketing Agreement With Servier Canada 30
Spectrum Pharma Enters into Agreement with Servier Canada 31
Crossbeta Biosciences Enters into Research Agreement with Servier Labs 32
Vect-Horus Enters into Agreement with Servier 33
GeNeuro Amends Co-Development Agreement with Servier for GnbAC-1 34
Servier Enters into Research Agreement with Walter and Eliza Hall Institute of Medical Research 35
Servier Expands Agreement with Novartis 36
Cellectis Enters Into Co-Development Agreement With Servier 37
Institut Curie Extends Research Agreement with Servier 39
Servier Enters Into Co-Development Agreement With Xention For XEN-D0103 40
Servier Enters Research Collaboration With Singapore Immunology Network For Anti-Cancer Drugs 41
Servier Exercises its Option from Amgen to Commercialize Omecamtiv Mecarbil 42
Afraxis And Servier Enter Into Agreement To Discover Drugs For CNS Disorders 43
NovAliX And Servier Enter Into Drug Discovery Agreement with Les Laboratoires 44
Servier Enters Into R&D Agreement With Florey Institute of Neuroscience and Mental Health 45
Les Labs Servier Enters Into Research Agreement With Monash Institute 47
Vernalis Enters Into Co-Development Agreement With Les Laboratoires Servier 48
Licensing Agreements 49
Les Laboratoires Servier Exercises Option for Licensing Agreement with Galapagos 49
Servier Enters into Licensing Agreement with Numerate 50
Les Laboratoires Servier Enters into Licensing Agreement with ILTOO Pharma 51
Les Laboratoires Servier Enters into Licensing Agreement with Neurochlore 52
Les Laboratoires Servier Enters into Licensing Agreement with Pieris Pharma 53
OSE Immunotherapeutics Enters into Option Licensing Agreement with Les Laboratoires Servier 55
Ilkos Therapeutics Enters into Licensing Agreement with Servier Canada 56
Les Laboratoires Servier Enters into Licensing Agreement with Sorrento Therapeutics 57
Pfizer Enters into Licensing Agreement with Servier for UCART19 58
Servier Exercises Option for Licensing Agreement with Cellectis 59
Horizon Discovery Enters into Licensing Agreement with Servier Lab 61
Sumitomo Dainippon Pharma Enters into Licensing Agreement with Servier Lab 62
Taiho Pharma Enters into Licensing Agreement with Servier 63
Servier Receives Rights of ITCA 650 from Intarcia Therapeutics 64
Servier Expands Licensing Agreement with CTI BioPharma for Pixuvri 65
Celladon Enters Into Option For Licensing Agreement With Servier 67
MacroGenics Exercised Option For Licensing Agreement With Servier For DART Products 68
BioInvent International Enters Into Licensing Agreement With Les Laboratoires Servier 70
Servier Enters Into Licensing Agreement With Shanghai Institute Of Materia Medica 71
Nerviano Medical Sciences And Servier Enter Into Licensing Agreement For Anticancer Drug 72
Asset Transactions 74
XOMA Acquires US Rights To Perindopril Franchise From Les Laboratoires Servier 74
Acquisition 75
Servier Completes Acquisition of Remaining 49.09% Stake in Egis Pharma For USD483 Million 75
Les Laboratoires Servier SAS-Key Competitors 77
Les Laboratoires Servier SAS-Key Employees 78
Les Laboratoires Servier SAS-Locations And Subsidiaries 79
Head Office 79
Other Locations & Subsidiaries 79
Recent Developments 83
Financial Announcements 83
Feb 22, 2018: Servier Announces 2017 annual results 83
Feb 07, 2017: Servier announces an increase in turnover for 2015-2016 85
Corporate Communications 86
Mar 06, 2018: Servier appoints a Chief Patient Officer 86
Product News 87
10/13/2017: New Formulation of ONCASPAR (pegaspargase) Receives Positive CHMP Opinion in Europe for Patients with Acute Lymphoblastic Leukemia 87
03/09/2017: Servier and Pfizer Announce FDA Clearance of IND Application for UCART19 in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia 88
Product Approvals 89
Feb 28, 2018: U.S. FDA Accepts Shires Biologics License Application for Calaspargase Pegol (Cal-PEG) for Acute Lymphoblastic Leukemia 89
Dec 13, 2017: New Formulation of ONCASPAR (pegaspargase) Receives Marketing Authorization in Europe for Patients with Acute Lymphoblastic Leukemia 90
Clinical Trials 91
Mar 08, 2018: Servier and Pfizer Announce Results of UCART19 First-in-Human Trials to Be Presented at the 44th EBMT (European Society for Blood and Marrow Transplantation) Annual Meeting 91
Dec 12, 2017: Preliminary Data from Servier and Pfizer's UCART19 Product Candidate Shows High Complete Remission Rate Across Two Phase I Adult and Pediatric Acute Lymphoblastic Leukemia Trials 92
Nov 01, 2017: Servier and Pfizer Announce Preliminary Results of the First-in-Human Trials of UCART19 Will Be Presented at the 59th American Society of Hematology (ASH) Annual Meeting 93
Other Significant Developments 94
Jul 04, 2018: Servier Netherlands mobilizes for Stem Cell Donation 94
Appendix 95
Methodology 95
About GlobalData 95
Contact Us 95
Disclaimer 95
List of Figure
List of Figures
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Les Laboratoires Servier SAS, Medical Devices Deals, 2012 to YTD 2018 11
List of Table
List of Tables
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Les Laboratoires Servier SAS, Deals By Therapy Area, 2012 to YTD 2018 10
Les Laboratoires Servier SAS, Medical Devices Deals, 2012 to YTD 2018 11
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Les Laboratoires Servier Acquires Oncology Business from Shire for USD2.4 Billion 16
Egis Pharma Acquires Sorbifer Rights from AstraZeneca 18
Ilkos Therapeutics Raises USD14 Million in Seed Financing 19
Laboratorios Farmaceuticos Rovi Enters into Agreement with Biogaran 20
Les Laboratoires Servier and ScandiCure Enter into Agreement 21
ImmunoQure Enters into Agreement with Servier 22
Les Laboratoires Enters into Agreement with Treventis 23
Les Laboratoires Servier Enters into Agreement with Harvard University 24
Philochem Enters into Research Agreement with Les Laboratoires Servier 25
Servier and Transgene Enters into Research Agreement 26
Vernalis and Servier Enter into Discovery Agreement 27
Les Laboratoires Servier and Masthercell Enter into Agreement 28
Les Laboratoires Servier Enters into Research Agreement with Center for Applied Medical Research 29
Daiichi Sankyo Enters Into Marketing Agreement With Servier Canada 30
Spectrum Pharma Enters into Agreement with Servier Canada 31
Crossbeta Biosciences Enters into Research Agreement with Servier Labs 32
Vect-Horus Enters into Agreement with Servier 33
GeNeuro Amends Co-Development Agreement with Servier for GnbAC-1 34
Servier Enters into Research Agreement with Walter and Eliza Hall Institute of Medical Research 35
Servier Expands Agreement with Novartis 36
Cellectis Enters Into Co-Development Agreement With Servier 37
Institut Curie Extends Research Agreement with Servier 39
Servier Enters Into Co-Development Agreement With Xention For XEN-D0103 40
Servier Enters Research Collaboration With Singapore Immunology Network For Anti-Cancer Drugs 41
Servier Exercises its Option from Amgen to Commercialize Omecamtiv Mecarbil 42
Afraxis And Servier Enter Into Agreement To Discover Drugs For CNS Disorders 43
NovAliX And Servier Enter Into Drug Discovery Agreement with Les Laboratoires 44
Servier Enters Into R&D Agreement With Florey Institute of Neuroscience and Mental Health 45
Les Labs Servier Enters Into Research Agreement With Monash Institute 47
Vernalis Enters Into Co-Development Agreement With Les Laboratoires Servier 48
Les Laboratoires Servier Exercises Option for Licensing Agreement with Galapagos 49
Servier Enters into Licensing Agreement with Numerate 50
Les Laboratoires Servier Enters into Licensing Agreement with ILTOO Pharma 51
Les Laboratoires Servier Enters into Licensing Agreement with Neurochlore 52
Les Laboratoires Servier Enters into Licensing Agreement with Pieris Pharma 53
OSE Immunotherapeutics Enters into Option Licensing Agreement with Les Laboratoires Servier 55
Ilkos Therapeutics Enters into Licensing Agreement with Servier Canada 56
Les Laboratoires Servier Enters into Licensing Agreement with Sorrento Therapeutics 57
Pfizer Enters into Licensing Agreement with Servier for UCART19 58
Servier Exercises Option for Licensing Agreement with Cellectis 59
Horizon Discovery Enters into Licensing Agreement with Servier Lab 61
Sumitomo Dainippon Pharma Enters into Licensing Agreement with Servier Lab 62
Taiho Pharma Enters into Licensing Agreement with Servier 63
Servier Receives Rights of ITCA 650 from Intarcia Therapeutics 64
Servier Expands Licensing Agreement with CTI BioPharma for Pixuvri 65
Celladon Enters Into Option For Licensing Agreement With Servier 67
MacroGenics Exercised Option For Licensing Agreement With Servier For DART Products 68
BioInvent International Enters Into Licensing Agreement With Les Laboratoires Servier 70
Servier Enters Into Licensing Agreement With Shanghai Institute Of Materia Medica 71
Nerviano Medical Sciences And Servier Enter Into Licensing Agreement For Anticancer Drug 72
XOMA Acquires US Rights To Perindopril Franchise From Les Laboratoires Servier 74
Servier Completes Acquisition of Remaining 49.09% Stake in Egis Pharma For USD483 Million 75
Les Laboratoires Servier SAS, Key Competitors 77
Les Laboratoires Servier SAS, Key Employees 78
Les Laboratoires Servier SAS, Subsidiaries 79
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.